Andres Gomez, Associate Professor of Hematology at UANL, recently shared a poll on X regarding the optimal management of a young patient with advanced Hodgkin lymphoma and a bulky mediastinal mass:
“Young person with advanced Hodgkin lymphoma and bulky mediastinal mass. Received Nivo-AVDx6.
Interim PET Deauville 3, end-of-treatment PET Deauville 4 uptake in original bulky mass.”
The results of the poll are:
- RT consolidation – 38.5%
- Monitor – 34.4%
- Second line Rx – 20.7%
- Nivo maintenance – 6.3%.
More posts featuring Andres Gomez.